Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
MedPacto logo — company profile

MedPacto

Founded 2013 Korea South Korea South 24 employees

General Information

Company Name MedPacto
Founded Year 2013
Location Korea South Korea South +1
Employees 24
Social

Get notified when MedPacto moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About MedPacto

MedPacto is a genome-based drug discovery and clinical-stage biotechnology company that is pursuing the development of first-in-class therapies to bring new hope to patients suffering from the most challenging diseases such as cancer. The leading drug candidate is Vactosertib, an orally bioavailable small-molecule inhibitor of the TGF-β type I receptor (TβRI) currently in phaseⅡ clinical trials with global pharmaceutical companies such as Merck and AstraZeneca. Vactosertib inhibits transforming growth factor-beta (TGF-β) pathway signaling, which is known to promote the metastasis and proliferation of cancer cells by modulating the tumor microenvironment. Vactosertib plays a synergistic role in improving the response to various therapies by inhibiting immune-suppressive TGF-β activity and suppressing the resistance mechanism of cancer stem cells. MedPacto is currently conducting combination trials with Vactosertib targeting several cancer indications including colorectal cancer, pancreatic cancer, sarcomas, NSCLC, bladder cancer, and gastric cancer. Additionally, MedPacto is currently developing MP005A, a new antibody therapeutics targeting BAG2 protein which promotes tumor formation and lung metastasis by binding the enzymes that regulate the tumor microenvironment in cancer development, and MP005D, a diagnostic kit that can detect BAG2 genes.

No funding data available for MedPacto yet.

Get notified when MedPacto raises funding

MedPacto Alternatives & Competitors

MedPacto vs
Senex Biotechnology. Inc.
Senex Biotechnology. Inc.

Preventing Adaptive Drug Resistance and Cancer Metastasis

Debt Financing
5 employees
Biotechnology, Health and Wellness
MedPacto vs
Bicara Therapeutics
Bicara Therapeutics United States

Pioneering bifunctional antibodies for targeted tumor modulation

IPO
123 employees
Biopharma, Biotechnology
MedPacto vs
Mestastop® Solutions
Mestastop® Solutions United States

Stopping Metastasis, giving life a second chance

Seed
18 employees
Biotechnology, Life Sciences

FAQ About MedPacto

MedPacto is a genome-based drug discovery and clinical-stage biotechnology company that is pursuing the development of first-in-class therapies to bring new hope to patients suffering from the most challenging diseases such as cancer. The leading drug candidate is Vactosertib, an orally bioavailable...
MedPacto was founded in 2013.
MedPacto is headquartered in Korea South.
MedPacto has approximately 24 employees.
Top alternatives and competitors to MedPacto include Senex Biotechnology. Inc., Bicara Therapeutics, Mestastop® Solutions, Teclison, IO Biotech. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
MedPacto and Senex Biotechnology. Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors MedPacto and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy